GRTX
Galera Therapeutics, Inc.
Key Financials
Operating Income
$-2542000
↑ 87.4%
Net Income
$149.0M
↑ 886.2%
EPS (Diluted)
$0.64
↑ 288.2%
Total Liabilities
$645000.00
↓ 99.6%
Total Assets
$7.2M
↓ 28.8%
Operating Cash Flow
$-6049000.00
↑ 50.2%
Cash & Equivalents
$6.4M
↓ 23.1%
Shareholders' Equity
$4.0M
↑ 102.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEFM14C | 7/2/2026 | View on SEC |
| SCHEDULE 13D | 6/11/2026 | View on SEC |
| 425 | 6/2/2026 | View on SEC |
| 425 | 6/2/2026 | View on SEC |
| SCHEDULE 13D/A | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 425 | 5/22/2026 | View on SEC |
| 425 | 5/21/2026 | View on SEC |
| 8-K | 5/19/2026 | View on SEC |
| 8-K | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GRTX |
| Company Name | Galera Therapeutics, Inc. |
| CIK | 1563577 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 610-725-1500 |